Mepolizumab
Mechanism :
Mepolizumab is an interleukin-5 antagonist (IgG1 kappa), it thus reduces the production and survival of eosinophils.
Indication :
- Asthma: Add-on maintenance treatment of severe asthma pediatric patients ≥12 years of age with an eosinophilic phenotype
- Eosinophilic granulomatosis with polyangiitis
Contraindications :
Hypersensitivity to mepolizumab or any component of the formulation.
Dosing :
Asthma:
Children ≥12 years and Adolescents:
Subcutaneous: 100 mg once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis (treatment):
Subcutaneous:
300 mg once every 4 weeks.
Adverse Effect :
Headache, injection site reactions, fatigue, eczema, pruritus, upper abdominal pain, UTI, hypersensitivity reactions, immunogenicity, influenza, back pain, muscle spasm.
Interaction :
No known significant interactions.
Hepatic Dose :
No dose adjustments are recommended.